Plain-English translation of NCT06166576 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment called TheraSphere, which uses tiny glass microspheres containing radioactive material to deliver radiation directly to liver cancer tumors. The treatment is designed for people with advanced hepatocellular carcinoma (liver cancer) whose cancer has started to invade blood vessels in the liver. Researchers want to see how well this targeted radiation approach works and how safe it is over a two-year follow-up period.
Advanced liver cancer that has grown into the blood vessels supplying the liver is very difficult to treat with standard methods. This medication offers a way to deliver high doses of radiation directly to the tumor while trying to spare the healthy liver tissue around it.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the radioembolization treatment using TheraSphere glass microspheres as your primary cancer treatment. Before treatment, you will have imaging tests to make sure you are a good candidate. After receiving the treatment, you will have regular follow-up visits and imaging scans over two years to monitor how well it is working and check for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
South Korea